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A B S T R A C T
Efficient induction of defined lineages in pluripotent stem cells constitutes the determinant step for the generation of ther-
apeutically relevant replacement cells to potentially treat a wide range of diseases, including diabetes. Pancreatic differ-
entiation has remained an important challenge in large part because of the need to differentiate uncommitted pluripotent
stem cells into highly specialized hormone-secreting cells, which has been shown to require a developmentally informed
step-by-step induction procedure. Here, in the framework of using induced pluripotent stem cells (iPSCs) to generate pan-
creatic cells for pancreatic diseases, we have generated and characterized iPSCs from Pdx1-GFP transgenic mice. The use
of a GFP reporter knocked into the endogenous Pdx1 promoter allowed us to monitor pancreatic induction based on the
expression of Pdx1, a pancreatic master transcription factor, and to isolate a pure Pdx1-GFP+ population for downstream
applications. Differentiated cultures timely expressed markers specific to each stage and end-stage progenies acquired a
rather immature beta-cell phenotype, characterized by polyhormonal expression even among cells highly expressing the
Pdx1-GFP reporter. Our findings highlight the utility of employing a fluorescent protein reporter under the control of a
master developmental gene in order to devise novel differentiation protocols for relevant cell types for degenerative dis-
eases such as pancreatic beta cells for diabetes.
© 2016 Published by Elsevier Ltd.
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1. Introduction
Induced pluripotent stem cells (iPSCs) offer a superior advantage
over embryonic stem cells (ESCs) in that they are capable of generat-
ing immune-compatible replacement cells and patient-specific disease
models for a wide range of diseases (Robinton and Daley, 2012). The
rate-limiting step, however, for any application to emerge from both
iPSCs and ESCs is their efficient and correct differentiation towards
relevant cell types, such as pancreatic beta cells for the treatment and
study of diabetes mellitus (Soria et al., 2015).
Most differentiation protocols towards the pancreas have been de-
signed based on principles of development (Spence and Wells, 2007).
With the administration of cytokines, growth factors, and small mole-
cules, pluripotent stem cells have been coaxed in vitro to differentiate
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following a sequence of steps leading to the pancreatic beta cell. After
passing through a transient primitive streak-like mesendoderm stage
(Tada et al., 2005), pluripotent stem cells differentiate into a Sox17+
and FoxA2+ population known as the definitive endoderm (DE), the
germ layer responsible for forming major organs like the liver, pan-
creas, lung, gut, and intestine (Wells and Melton, 1999). This step
is mediated by exposure to high concentrations of TGF-beta family
member Activin-A, which has been shown to mimic the functions of
co-member Nodal in endoderm induction (Kubo et al., 2004).
DE cells, upon the repression of sonic hedgehog (Shh) signaling
(Hebrok et al., 1998) activate the pancreatic program centered on the
homeobox gene Pdx1 (Jonsson et al., 1994) which marks all pancre-
atic derivatives. Pdx1+ epithelia have been shown to be capable of
proliferation as progenitors (Zhou et al., 2007), and, during a narrow
timeframe during embryogenesis, are decisive in determining the final
organ size of the pancreas (Stanger et al., 2007). The suppression of
Notch (Apelqvist et al., 1999) later promotes the specification of the
endocrine lineage. The final step is the maturation of endocrine prog-
enitors into insulin-producing beta cells.
Numerous reports have described differentiation of pluripotent
stem cells in vitro towards the aforementioned developmental stages:
definitive endoderm (Kubo et al., 2004; D'Amour et al., 2005;
Yasunaga et al., 2005), pancreatic endoderm (Kroon et al., 2008;
Ku et al., 2004; Micallef et al., 2005), and insulin-producing cells
(D'Amour et al., 2006; Pagliuca et al., 2014; Rezania et al., 2014;
Russ et al., 2015). Despite these considerable advances, many unre-
solved issues remain like the heterogeneity of differentiated cultures,
http://dx.doi.org/10.1016/j.diff.2016.04.005
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the irreproducibility of published protocols due to clonal variability
and intrinsic differences in laboratory conditions, and the inefficient
production of mature differentiated cell types. In this report, we gen-
erated reporter iPSCs from transgenic Pdx1-GFP knock-in mice and
differentiated them towards pancreatic cells using a novel protocol. At
the end of the differentiation, we sorted Pdx1-GFP+ cells and detected
expression of multiple hormone markers, showing induction of en-
docrine cells, albeit with an immature phenotype. These findings con-
tribute to the large body of evidence of the pancreatic differentiation
potential of iPSCs and may aid towards the design of a more robust
pancreatic differentiation protocol for a wide range of pluripotent cell
lines.
2. Materials and methods
2.1. Generation of iPSCs
iPSCs were generated from Pdx1-GFP knock-in reporter mouse
(Gu et al., 2002)-derived mouse embryonic fibroblasts (MEFs) by
the retroviral transduction of Oct4, Sox2, and Klf4 (Addgene) as
published with minor modifications (see Supplementary Methods)
(Takahashi and Yamanaka, 2006). iPSC colonies were picked up on
day 20 post-infection and expanded as stable clones under standard
ESC culture conditions. For details of iPSC generation and character-
ization, see Supplementary Methods.
2.2. Cells
Mouse iPSCs and ESCs were maintained on mitomycin-C
(Sigma)-inactivated MEFs in ESC medium containing DMEM with
4.5 g/l glucose (Gibco), 15% fetal bovine serum (Hyclone), 103 U/l
leukemia inhibitory factor (Millipore), 1× MEM non-essential amino
acids (Gibco), 2 mM L-glutamine (Lonza), 0.1 mM beta-mercap-
toethanol (Gibco), and 1× penicillin/streptomycin (Gibco). Cells were
trypsinized with 0.05% trypsin/EDTA (Gibco) and passaged at 1:6 or
higher every 2–3 days.
2.3. Pancreatic differentiation of iPSCs
iPSCs were previously grown for one passage on 0.1% gelatin
(Millipore) to dilute MEF feeders. After two days, iPSCs were seeded
on 12-well plates coated with 2% growth factor-reduced Matrigel
(BD) at 5000 cells/cm2. Cells were maintained continuously in basal
differentiation medium containing DMEM with 1 g/l glucose (Gibco),
40% MCDB 201 (Sigma), 100 µM L-ascorbic acid (Sigma), 0.25×
linoleic acid/BSA (Sigma), 0.25× ITS (Sigma), 50 µM beta-mercap-
toethanol (Gibco), and 1× penicillin/streptomycin (Gibco). Cells were
treated with the following cytokines and small molecules as follows
with medium change every other day (Fig. 2): days 1–3: 100 ng/ml
Activin-A (R&D) and 50 ng/ml Wnt3a (R&D) in 2% FBS; days 3–6:
100 ng/ml Activin-A only in 1% FBS; days 6–8: 2.5 µg/ml mono-
clonal Shh antibody (R&D), 2 µM all-trans RA (Sigma), 50 ng/ml
KGF (R&D), and 100 ng/ml noggin (R&D) in 0.5% FBS; days 8–10:
same previous medium was used but without noggin; days 10–16:
50 ng/ml KGF and 50 ng/ml heparan sulfate (Sigma) without serum;
and days 16–22: 50 ng/ml betacellulin (R&D), 10 nM exendin-4
(Sigma), 10 mM nicotinamide (Sigma), and 50 ng/ml GDF11 (R&D)
without serum.
2.4. qpcr analysis
Total RNA was isolated from cultured cells using the RNAEasy
Micro Kit (Qiagen). Reverse transcription was performed using the
Superscript II RT kit (Invitrogen) and quantitative PCR (qPCR) using
the SYBR Green Master Mix (Invitrogen). qPCR was carried out us-
ing the ECycler1000 thermocycler (Eppendorf). qPCR data were ex-
pressed in Delta-Ct values, i.e., Ct values of gene of interest – Ct val-
ues of housekeeping gene Gapdh (Fig. 1c and d), in relative expres-
sion, i.e., fold-change values with respect to day 0 (Figs. 3a, 4a and c),
or in Log fold-change, i.e., logarithm of fold-change compared to day
0 (Fig. 5c).
2.5. Immunofluorescence
Cells were fixed in 10% neutral buffered formalin for 30 min,
washed with PBS, and then blocked and permeabilized with 5% horse
serum, 3% bovine serum albumin (BSA) (Sigma), and 0.3% Triton
X-100 (Sigma) in PBS for another 30 min. Primary antibodies were
added in their appropriate dilutions in 1% serum (from the same
species as the source of their corresponding secondary antibodies), 3%
BSA, and 0.1% Triton X-100 in PBS overnight at 4 °C. The next day,
secondary antibodies were added in the same antibody diluent at 1:500
and incubated for 1 h and 30 min at room temperature in dark. Nu-
clei were stained with Hoechst (4 µg/ml) (Sigma) in simultaneous in-
cubation with the secondary antibody. Washes with 1× PBS were per-
formed in between steps except before incubation with primary anti-
body.
For double immunostaining, procedure from the blocking and per-
meabilization step and onwards was repeated after the first secondary
antibody incubation on the second day. Cells were incubated with the
second set of primary antibodies overnight at 4 °C. Co-staining with
the second set of secondary antibodies and Hoechst was done on the
third day. Cells were viewed under an inverted fluorescence micro-
scope (Zeiss).
2.6. Cell sorting
Day 22 cultures were dissociated with treatment of dispase (BD)
for 30 min followed by 0.25% trypsin/EDTA (Gibco) for 10 min at
37 °C until they could be mechanically disaggregated into single cells
with a micropipette. Cells were resuspended in flow cytometry buffer
(3% FBS, 25 mM HEPES, 5 mM EDTA in PBS) and maintained at
4 °C ready for cell sorting. Prior to sorting, cell viability was assessed
by Trypan blue dye exclusion. Sorting gates were set for GFP+ popu-
lation. GFP+ cells were analyzed and separated with the FACSAria II
cytometer (BD). Debris, doublets, and dead cells were all excluded by
forward scatter, side scatter, and TOPRO gating. Gating was imple-
mented based on staining profiles of undifferentiated iPSCs as nega-
tive control. A post-sorting analysis was performed for both GFP+ and
GFP– cells to ensure purity of sorted populations. Sorted cells were
collected in lysis buffer (Qiagen) in preparation for RNA analysis.
2.7. Statistics
Statistical analysis of qPCR data was performed using 1-way
ANOVA followed by a Bonferroni's multiple comparison test on
mean-centered values using the GraphPad Prism Version 6 software.
Mean-centered values were calculated as previously described
(Willems et al., 2008) in order to normalize highly variable data
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Fig. 1. Characterization of Pdx1-GFP iPSC clones. (a) Brightfield micrograph of representative iPSC clone resembling ESCs in morphology. (b) Staining for alkaline phosphatase.
(c) Retroviral silencing of exogenous factors detected by qPCR using primers that specifically detect endogenous (Endo) and exogenous or transgenic (Tg) transcripts; data expressed
in Delta-Ct or change in cycle thresholds (i.e., CtGapdh–CtGene) with respect to housekeeping gene Gapdh (n=2 clones in triplicates). (d) Induction of ESC markers detected by qPCR;
data expressed in Delta-Ct (n=2 clones in triplicates). Oct4, Sox2, and Klf4 transcripts were detected from endogenous (Endo) loci. (e) Immunostaining for Oct4, Nanog, Sox2, and
SSEA1 in representative iPSC clone. Nuclei stained with Hoechst. (f) Teratoma formation of representative iPSC clone showing tissues of the three germ layers.
across biological replicates. Statistical significance is indicated as fol-
lows: * p<0.05; ** p<0.01; *** p<0.001.
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Fig. 2. Pancreatic differentiation protocol. Schematic diagram of differentiation protocol in four stages: definitive endoderm (days 0–6), pancreatic endoderm (days 7–10), endocrine
progenitors (days 11–16), and insulin-expressing cells (days 17–22). Micrographs show sample differentiation cultures by stage: flat, polygonal endoderm sheets by day 6, endoge-
nous Pdx1 activation by day 10, Pdx1-GFP visualization by day 16, which increases significantly in number by day 22. Diagram also shows the cytokines and small molecules used
in the protocol, and the decreasing serum concentrations employed across the four stages.
Fig. 3. Definitive endoderm (DE) induction in iPSCs. (a) Induction of primitive streak markers Brachyury and Goosecoid and DE markers Cxcr4 and Sox17. n=2 experiments for one
clone. (b) Day 6 double immunostaining for FoxA2 and Hoechst (10× objective magnification), FoxA2 and Sox17 (20×), and Cxcr4 and FoxA2 (20×).
3. Results and discussion
3.1. Generation and characterization of iPSCs from Pdx1-GFP
reporter mice
Following a standard protocol (Takahashi et al., 2007), MEFs de-
rived from transgenic mice carrying a GFP reporter under the con-
trol of the endogenous Pdx1 promoter (Gu et al., 2002) were repro-
grammed into iPSCs using the three reprogramming factors Oct4,
Sox2, and Klf4 (Fig. 1a). Reprogramming factor Myc was omitted
from the reprogramming cocktail in order to achieve a more uniform
and complete reprogramming and to minimize in vivo tumorigenicity
due to the potential reactivation of retroviral Myc (Nakagawa et al.,
2008). While a lot more colonies were observed among Myc-infected
cultures, the probability of isolating partially or incompletely repro-
grammed clones, characterized by the absence of transgenic silencing
(Maherali and Hochedlinger, 2008), was higher in these cultures than
in Myc-free infected cells (data not shown). Thus, to avoid the possi-
bility of isolating partially or incompletely reprogrammed clones, all
work presented in this study was performed on Myc-free iPSCs.
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Fig. 4. Pancreatic induction in iPSCs. (a) Activation of pancreatic endoderm markers Hnf6, Pdx1, Hb9, and Nkx2.2 detected by qPCR. n=2 experiments for one clone. (b) Double
immunostaining for Pdx1 and Hoechst (day 10), FoxA2 and Pdx1 (day 10), and Pdx1 and Hoechst (day 22). All images were taken at 20x objective magnification. (c) Induction of
hormone markers Ins1 (Insulin1), Gcg (Glucagon), and Sst (Somatostatin) measured by qPCR. n=2 experiments for one clone.
Established iPSC clones expressed standard ESC markers such as
alkaline phosphatase (Fig. 1b), the endogenous reprogramming fac-
tors (Fig. 1c and e), along with the rest of the pluripotency genes such
as Rex1, Nanog, and Gdf3, among others (Fig. 1d). All clones tested
were also capable of generating teratomas containing tissues repre-
sentative of the three embryonic germ layers when subcutaneously
injected into immunocompromised mice (Fig. 1f). These data show
that at the level of morphology, growth properties, and expression of
pluripotency markers, iPSCs were highly similar to ESCs.
3.2. Sequential addition of developmentally relevant cytokines leads
to pancreatic induction
To standardize the protocol, we tested numerous parameters
known to influence pancreatic differentiation of pluripotent cells in
vitro: seeding density, culture substrates, serum concentration, and the
different cytokines, growth factors, and small molecules involved in
driving pancreatic specification in vivo.
After one passage of iPSCs on gelatin in the absence of feed-
ers, iPSCs were cultured as a monolayer at a low seeding density
(5000 cells/cm2) on Matrigel, a substrate previously used to differen-
tiate towards DE (Kubo et al., 2004; Yasunaga et al., 2005). Cells
were continuously cultured for 22 days in the presence of various cy
tokines and small molecules (Fig. 2), empirically chosen on the basis
of: (a) induction of a panel of stage-specific developmental markers,
and (b) induction of the Pdx1-GFP locus as monitored by GFP fluo-
rescence.
During the first six days (days 1–6), in the presence of high con-
centration of Activin-A (Kubo et al., 2004; Yasunaga et al., 2005),
Wnt3a (D'Amour et al., 2006), and in reduced serum conditions (Tada
et al., 2005), cells proliferated and grew flat epithelial patches (Suppl.
Fig. 1) that resembled endoderm cells as previously reported (Tada et
al., 2005). These cells expressed key DE markers FoxA2, Sox17, and
Cxcr4 in mRNA and protein (Fig. 3a and b). Primitive streak mark-
ers, Brachyury and Goosecoid, sharply peaked on or before day 6,
but went undetected immediately after (Fig. 3a), suggesting that cells
had passed through an intermediate mesendoderm stage (Tada et al.,
2005).
For the next four days (days 6–10), cells were exposed to signal-
ing molecules that drive pancreatic specification (Fig. 2): (a) mono-
clonal antibody against Shh (Hebrok et al., 1998), a less toxic sub-
stitute to the more routinely used KAAD-cyclopamine; (b) all-trans
retinoic acid (RA), inducer of dorsal pancreatic endoderm (Martín et
al., 2005); (c) keratinocyte growth factor (KGF), a factor that pro-
motes proliferation of pancreatic epithelia (Ye et al., 2005); and (d)
Noggin, a BMP inhibitor to exclude the hepatic fate (Mfopou et al.,
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Fig. 5. Sorted GFP+ cells express multiple hormone markers. (a) Fluorescence micrographs of Pdx1-GFP+ clusters on day 16 and 22 (both at 10× objective magnification). (b) Repre-
sentative flow cytometry analysis showing sorted GFP-negative (GFP neg), GFP low, and GFP high populations. (c) Detection of transcripts of Pdx1 and key hormone markers Ins1
(Insulin1), Ins2 (Insulin2), Gcg (Glucagon), and Sst (Somatostatin) in bulk (or unsorted) day 22 cultures, and sorted GFP-neg, GFP-low, and GFP-high populations. n=2 experiments
for one clone.
2010). Pdx1 transcripts (Fig. 4a) and proteins (Fig. 4c) were first de-
tected on day 10 and steadily increased towards the end of the protocol
(Fig. 4a and b). Hnf6, an upstream activator of Pdx1 (Jacquemin et al.,
2003), was activated on day 10 and maintained high levels throughout
the culture (Fig. 4a). Other markers of pancreatic epithelial precursors
like Hb9 and Nkx2.2 were likewise induced on day 10 (Fig. 4a), indi-
cating pancreatic endoderm induction.
To expand these Pdx1+ cells, KGF treatment was extended for
six more days (days 10–16) along with the addition of heparan sul-
fate (Fig. 2), a proteoglycan expressed in pancreatic epithelial base-
ment membrane and mesenchyme that maintains the pancreatic prog-
enitor pool and delays its differentiation (Zertal-Zidani et al., 2007),
and, upon the binding of KGF, promotes epithelial branching mor-
phogenesis (Makarenkova et al., 2009). On day 16, Pdx1 transcripts
increased by four-fold (Fig. 4a), corroborated by robust Pdx1 im
munostaining in later day 22 cultures (Fig. 4b). Co-immunostaining
for FoxA2 and Pdx1 confirms that Pdx1+ cells arise from previously
expressing FoxA2+ cells (Fig. 4b).
The final phase (days 16–22) consisted in treating cells with fac-
tors that favor beta-cell maturation and expansion in vitro (Fig. 2): be-
tacellulin (Huotari et al., 2002), exendin-4 (List and Habener, 2004),
nicotinamide (Otonkoski et al., 1993), and GDF11 (Harmon et al.,
2004). Day 22 cultures expressed islet hormone markers indicating the
cells had undergone pancreatic endocrine commitment. Transcripts
of Glucagon (Gcg), expressed by the α-cell, and Somatostatin (Sst),
by the δ-cell, were detected as early as in day 10 cultures and were
continued to be expressed by more than a 10,000- and 1000-fold,
respectively, whereas Insulin1 (Ins1), proper of the beta-cell, was
induced later at day 16 at levels similar to those of Pdx1 (Fig.
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4c). By contrast, the other insulin isoform, Insulin2 (Ins2), equally
functional in rodents as Ins1 (Giddings and Carnaghi, 1988) was not
detected in our cultures (data not shown). These data suggest that en-
docrine commitment of iPSCs in vitro in part resembles that of embry-
onic development in that Gcg-expressing cells arise earlier followed
by Ins-expressing ones, but differs in that Sst-expressing cells were
likewise induced earlier.
An important consideration in differentiation in vitro is the spon-
taneous induction of divergent lineages that could be occurring at
the expense of pancreatic differentiation. First, residual expression of
pluripotency marker Oct4 was considerably reduced especially after
day 6 (Suppl. Fig. 2a); however, it was still detected in end-stage cul-
tures, albeit in few clusters of cells (Suppl. Fig. 2b). The expression
of markers of primitive endoderm Sox7 and of visceral endoderm Afp
(Suppl. Fig. 2a) suggests induction of extraembryonic cells. However,
Sox7 is also known to mark mesoderm (Gandillet et al., 2009) and Afp
both embryonic mesoderm (Dziadek and Adamson, 1978) and early
hepatoblasts (Gualdi et al., 1996), suggesting that their induction may
not be completely due to the extraembryonic lineage. Besides, the
highest Sox7 induction occurred much later at day 16 (Suppl. Fig. 2a),
arguing in part its expression in mesoderm-derived cells, which in the
context of pancreatic differentiation could possibly be participating in
crucial epithelial-mesenchymal interactions (Jacquemin et al., 2006).
On the other hand, the other more mature liver marker, Albumin (Alb),
was only mildly induced towards the end of the protocol compared to
Afp (Suppl. Fig. 2a), which does not rule out completely hepatic in-
duction. Lastly, neuroectoderm marker Sox1 was not detected at any
stage of the protocol (data not shown). Thus, more than having yielded
liver, cells might have spontaneously differentiated into non-pancre-
atic lineages that mainly include the mesoderm and the primitive en-
doderm.
3.3. Pdx1-GFP+ cells arise in culture on day 16
The main advantage of using a Pdx1-GFP knock-in reporter line is
the ability to monitor induction by visualizing GFP fluorescence. De-
spite induction of Pdx1 at both mRNA and protein levels earlier on
day 10 (Fig. 4a and b), cells did not appear Pdx1-GFP+ till around day
16 (Fig. 5a), suggesting that KGF treatment was necessary to expand
nascent Pdx1+ cells in culture confirming published data on pancreatic
tissue explants (Ye et al., 2005). Pdx1-GFP+ cells formed in clusters
that proliferated towards the end of the protocol (Fig. 5a). The appar-
ent discrepancy in the timing of detection between induction of the
Pdx1-GFP locus and endogenous Pdx1 may be due to the weak inten-
sity of the reporter at earlier timepoints when there is assumingly less
Pdx1 expression, as immunostaining of day 10 cultures detected GFP+
cells (Suppl. Fig. 3). Finally, GFP+ cells were also verified by double
immunostaining to be simultaneously co-expressing Pdx1 (Suppl. Fig.
3) confirming non-leaky expression of the reporter transgene.
3.4. Pdx1-GFP+ cells have an immature endocrine phenotype
The Pdx1-GFP knock-in reporter system allows the isolation of
a pure population of differentiated Pdx1+ pancreatic cells. From day
22 cultures (Fig. 5a), by cell sorting, both GFPhigh and GFPlow pop-
ulations were isolated (Fig. 5b). Both GFPhigh and GFPlow cells ex-
pressed high levels of Ins1, Gcg, and Sst, with higher induction in the
GFPhigh population as expected, while no induction was observed in
the GFP− population (Fig. 5c). Ins2, undetected in bulk cultures, was
detected only in the GFPhigh population, suggesting that high levels of
Pdx1 are required for this marker (Fig. 5c). Interestingly, the GFP−
population, while negative for Ins1, Ins2, and Sst, expressed compar-
atively high levels of Gcg, suggesting the induction of either a signif-
icant number of α-cells or of cells that had undergone primary transi-
tion as in development (Gittes, 2009). The co-expression of all three
hormones in the GFP+ population indicates the immature phenotype
of the pancreatic endocrine cells generated.
Here, we have described a novel pancreatic differentiation proto-
col using a fluorescent reporter indicative of expression of master pan-
creatic transcription factor Pdx1. As in other in vitro protocols, differ-
entiated progenies yielded an immature pancreatic endocrine pheno-
type marked by polyhormonal expression (Hrvatin et al., 2014). Fur-
ther maturation could be enhanced by in vivo transplantation (Kroon
et al., 2008; Rezania et al., 2012) or, theoretically, by adding beta-cell
maturation and expansion factors as observed in tissue explant exper-
iments (List and Habener, 2004).
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